Article History
Accepted: 4 May 2021
First Online: 22 June 2021
Competing interests
: S.E.Q. has applied for patents related to therapeutic targeting of the ANGPT–TEK pathway in ocular hypertension, glaucoma and kidney disease, receives research support, owns stocks in and is a director of Mannin Research, is an external advisory board member of AstraZeneca and receives consulting and advisory board fees from Roche, Janssen, Genentech and AstraZeneca. The other authors declare no competing interests.